AGM.L

Applied Graphene Materials Plc
Applied Graphene - Update on Annual Report and Accounts
26th January 2023, 13:50
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 0079O
Applied Graphene Materials PLC
26 January 2023
 

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

26 January 2023

Applied Graphene Materials plc

("Applied Graphene Materials", the "Company" or the "Group")

FY22 Annual Report and Accounts

Further to the Company's announcement on 13 January 2023, the Board now confirms that the Company's annual report and accounts for the year ended 31 July 2022 ("FY22") will not be published by 31 January 2023, being the deadline for publication stipulated under the AIM Rules for Companies. Consequently, the Company's shares will be suspended from trading on AIM with effect from 1 February 2023, pending publication of the FY22 annual report and accounts.

The Board confirms that the previously notified strategic review is ongoing and it remains the Board's intention to enter into a legally binding contract for a transaction (involving either the sale of the Group's trade and assets or of the shares in the Company's main operating subsidiary) by 31 January 2023 or as soon as reasonably practicable thereafter. Discussions may be altered or terminated at any point and, accordingly, there can be no certainty as to entry into such a contract nor as to its terms.

The Board continues to take action to seek to protect the financial position of the Company, its shareholders and creditors in the event that the strategic review does not achieve a satisfactory result. In parallel with the strategic review, the process of statutory redundancy consultations with the Group's employees announced on 23 November 2022 is ongoing.

The Board will continue to provide further updates as appropriate.

For further information, please contact:

Applied Graphene Materials  +44 (0) 1642 438 214

Adrian Potts, Chief Executive Officer

David Blain, Chief Financial Officer

Alvarez & Marsal Europe LLP +44 (0) 784 107 2042

Alex Baird  abaird@alvarezandmarsal.com

Singer Capital Markets  (Nominated Adviser and Joint Broker) +44 (0) 207 496 3000

Peter Steel / Oliver Platts

Allenby Capital Limited (Joint Broker) +44 (0) 203 328 5656

Nick Athanas / Dan Dearden-Williams (Corporate Finance)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSSEDFDMEDSELF ]]>
TwitterFacebookLinkedIn